Cerebellar Pathology in Forensic and Clinical Neuroscience
Ageing Research Reviews,
Год журнала:
2025,
Номер
unknown, С. 102697 - 102697
Опубликована: Фев. 1, 2025
Язык: Английский
Role of tau versus TDP‐43 pathology on medial temporal lobe atrophy in aging and Alzheimer's disease
Alzheimer s & Dementia,
Год журнала:
2025,
Номер
21(2)
Опубликована: Фев. 1, 2025
Abstract
Hippocampal
atrophy
on
magnetic
resonance
imaging
is
an
important
biomarker
in
Alzheimer's
disease
(AD).
While
hippocampal
was
thought
to
result
from
tau
tangles
AD,
different
neuropathologies
can
lead
atrophy,
especially
TAR
DNA‐binding
protein
43
(TDP‐43)
pathology.
In
this
narrative
review,
we
evaluate
existing
studies
the
relative
contribution
of
and
TDP‐43
pathology
medial
temporal
lobe
(MTL)
atrophy.
We
report
a
clear
association
both
neuropathology
with
MTL
even
after
correcting
for
other
neuropathologies.
Next,
discuss
potential
synergism
between
timing
effects
Finally,
avenues
future
research
will
be
discussed.
A
better
understanding
interplay
their
effect
help
development
more
specific
biomarkers
limbic‐predominant
age‐related
encephalopathy
pinpointing
optimal
testing
anti‐tau
anti‐TDP‐43
treatments
trials.
Highlights
Both
contribute
There
positive
potentially
synergism.
It
unclear
if
have
additive
or
synergistic
The
remains
unclear.
Clarifying
improve
biomarkers.
Язык: Английский
Selective imaging probes for differential detection of pathological tau polymorphs in tauopathies
Drug Discovery Today,
Год журнала:
2025,
Номер
unknown, С. 104352 - 104352
Опубликована: Апрель 1, 2025
Tauopathies,
including
Alzheimer's
disease
(AD),
Pick's
(PiD),
progressive
supranuclear
palsy
(PSP)
and
corticobasal
degeneration
(CBD),
are
characterized
by
the
misfolding
pathological
aggregation
of
tau
protein,
leading
to
neurodegeneration.
Although
pathogenesis
these
diseases
is
still
a
matter
for
debate,
formation
amyloid
inclusions
represents
only
histopathological
hallmark
available.
Tau
not
same
in
terms
structure
morphology,
different
tauopathies
polymorphs.
Remarkably,
selective
detection
polymorphs
crucial
differential
diagnosis,
monitoring
evaluation
potential
harmfulness
polymorphs,
with
significant
impact
on
drug
discovery.
This
review
discusses
recent
advances
development
imaging
probes
designed
forms
associated
specific
tauopathies.
We
explore
application
compounds
that
can
target
characteristic
AD,
PiD,
PSP
CBD.
In
particular,
we
focus
discussing
probes'
selectivity
sensitivity
distinguishing
between
tauopathy-associated
preclinical
settings.
The
progress
weaknesses
this
field
discussed,
guide
researchers
identifying
accurate
potent
diagnosis
neurodegenerative
diseases.
Язык: Английский
Morphometry of medial temporal lobe subregions using high‐resolution T2‐weighted MRI in ADNI3: Why, how, and what's next?
Alzheimer s & Dementia,
Год журнала:
2024,
Номер
20(11), С. 8113 - 8128
Опубликована: Сен. 16, 2024
Abstract
This
paper
for
the
20th
anniversary
of
Alzheimer's
Disease
Neuroimaging
Initiative
(ADNI)
provides
an
overview
magnetic
resonance
imaging
(MRI)
medial
temporal
lobe
(MTL)
subregions
in
ADNI
using
a
dedicated
high‐resolution
T2‐weighted
sequence.
A
review
work
that
supported
inclusion
this
modality
into
Phase
3
is
followed
by
brief
description
MTL
and
analysis
protocols
summary
studies
have
used
these
data.
supplemented
new
study
uses
novel
surface‐based
tools
to
characterize
neurodegeneration
across
biomarker‐defined
AD
stages.
reveals
pattern
spreading
cortical
thinning
associated
with
increasing
levels
tau
pathology
presence
elevated
amyloid
beta,
apparent
epicenters
transentorhinal
region
inferior
hippocampal
subfields.
The
concludes
outlook
4.
Highlights
As
3,
protocol
includes
MRI
scan
optimized
subfields
subregions.
These
scans
are
processed
core
obtain
automatic
segmentations
derive
morphologic
measurements.
More
detailed
granular
examination
response
disease
progression
achieved
applying
modeling
techniques.
Surface‐based
gray
matter
loss
spatially
expanding
patterns
advancing
stages
(AD),
as
defined
based
on
positron
emission
tomography
biomarkers
accordance
recently
proposed
criteria.
closely
align
post
mortem
literature
spread
pathological
AD,
supporting
role
beta
driver
neurodegeneration.
Язык: Английский
Investigating the Interplay between Cardiovascular and Neurodegenerative Disease
Biology,
Год журнала:
2024,
Номер
13(10), С. 764 - 764
Опубликована: Сен. 26, 2024
Neurological
diseases,
including
neurodegenerative
diseases
(NDDs),
are
the
primary
cause
of
disability
worldwide
and
second
leading
death.
The
chronic
nature
these
conditions
lack
disease-modifying
therapies
highlight
urgent
need
for
developing
effective
therapies.
To
accomplish
this,
models
NDDs
required
to
increase
our
understanding
underlying
pathophysiology
evaluating
treatment
efficacy.
Traditionally,
have
focused
on
central
nervous
system
(CNS).
However,
evidence
points
a
relationship
between
systemic
factors
development
NDDs.
Cardiovascular
disease
related
risk
been
shown
modify
cerebral
vasculature
Alzheimer’s
disease.
These
findings,
combined
with
reports
changes
vascular
density
blood–brain
barrier
integrity
in
other
NDDs,
such
as
Huntington’s
Parkinson’s
disease,
suggest
that
cardiovascular
health
may
be
predictive
brain
function.
evaluate
we
explore
disruptions
circulatory
murine
CNS
summarize
combining
disruption
In
this
study,
aim
neurodegeneration
interactions
across
multiple
states
utility
model
systems.
Язык: Английский